{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:38:40Z","timestamp":1771000720721,"version":"3.50.1"},"reference-count":148,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ther. Deliv."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.4155\/tde-2020-0035","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T06:15:14Z","timestamp":1589350514000},"page":"245-268","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":106,"title":["COVID-19 Pandemic: an Overview of epidemiology, pathogenesis, Diagnostics and Potential Vaccines and Therapeutics"],"prefix":"10.1080","volume":"11","author":[{"given":"Haneen","family":"Amawi","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy\rDepartment of Pharmacy Practice\rYarmouk University\rIrbid\rJordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghina'a I","family":"Abu Deiab","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy\rDepartment of Medicinal Chemistry & Pharmacognosy\rYarmouk University\rIrbid\rJordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa A","family":"A Aljabali","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy\rDepartment of Pharmaceutics & Pharmaceutical Technology\rYarmouk University\rIrbid\rJordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-1159","authenticated-orcid":false,"given":"Kamal","family":"Dua","sequence":"additional","affiliation":[{"name":"Discipline of Pharmacy\rGraduate School of Health\rUniversity of Technology Sydney\rUltimo\rNSW\r2007\rAustralia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8499-9891","authenticated-orcid":false,"given":"Murtaza M","family":"Tambuwala","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences\rUlster University\rColeraine\rCounty Londonderry\rBT52 1SA\rNorthern Ireland\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2018.11.001"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.200902135"},{"key":"e_1_3_2_5_1","unstructured":"Cascella M RajnikM CuomoA DulebohnSC DiNapoli R. Features evaluation and treatment coronavirus (COVID-19). StatPearls Treasure Island (FL) (2020)."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40475-020-00201-6"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb6936"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2081803"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00650-10"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13196"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13077-2"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1211721"},{"key":"e_1_3_2_14_1","volume-title":"Report 2: Estimating the potential total number of novel Coronavirus cases in Wuhan City, China.","author":"Imai N","year":"2020","unstructured":"Imai N , DorigattiI , CoriA , DonnellyC , RileyS , FergusonNM. Report 2: Estimating the potential total number of novel Coronavirus cases in Wuhan City, China.Imperial College London (2020)."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2020.01.023"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.03.013"},{"key":"e_1_3_2_17_1","unstructured":"RVB . Division of viral diseases. Real-time rt-pcr panel for detection 2019- novel coronavirus. (2020).www.who.int\/docs\/default-source\/coronaviruse\/uscdcrt-pcr-panel-for-detectioninstructions.pdf?sfvrsn=3aa07934_2"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0820-9"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2606.200251"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2003.03011"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3528722"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-81-4-853"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.12.015"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.05.20031476"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-20"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa199"},{"key":"e_1_3_2_31_1","unstructured":"WHO . Coronavirus disease (COVID-2019) situation reports. (2020). www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2016.04.005"},{"key":"e_1_3_2_33_1","unstructured":"WHO . Novel coronavirus (2019-ncov) technical guidance: laboratory testing for 2019-ncov in humans. (2020). www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/technical-guidance\/laboratory-guidance"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00272"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2016.36.5.450"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-139"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.5812\/ircmj.23874"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1107.041045"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.11.064"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1086\/380841"},{"issue":"2","key":"e_1_3_2_42_1","first-page":"417","article-title":"Development of a Western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome","volume":"11","author":"He Q","year":"2004","unstructured":"He Q , ChongKH , ChngHHet al. Development of a Western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome. Clin. Diagn. Lab. Immunol.11(2), 417\u2013422 (2004).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.5.1994-1999.2004"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30260-9"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030623"},{"key":"e_1_3_2_46_1","unstructured":"Detection of 2019 novel coronavirus (2019-ncov) in suspected human cases by rt-pcr lks faculty of medicine school of public health 2020). www.who.int\/docs\/default-source\/coronaviruse\/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001105"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/mi11030306"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01628-17"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007236"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1739565"},{"key":"e_1_3_2_52_1","unstructured":"Bgi develops real-time fluorescent rt-pcr kit for detecting the 2019 novel coronavirus 2020). www.bgi.com\/global\/company\/news\/bgi-develops-real-time-dna-based-kit-for-detecting-the-2019-novel-coronavirus\/"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350701200702"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30002-1"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30266-X"},{"key":"e_1_3_2_56_1","unstructured":"Evaluate the safety tolerability and immunogenicity study of gls-5300 in healthy volunteers. (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03721718?term=vaccine&cond=Mers+CoV&draw=2&rank=7"},{"key":"e_1_3_2_57_1","unstructured":"Efficacy and safety of hydroxychloroquine for treatment of pneumonia caused by 2019-ncov (hc-ncov) 2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04261517"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/v12030254"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1740560"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.368.6486.14"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1756411"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005456117"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020183"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102538"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25688"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.26633\/RPSP.2020.40"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12005988.v2"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12003930.v1"},{"key":"e_1_3_2_70_1","unstructured":"Center for Disease Control and Prevention . Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). (2020). www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-guidance-management-patients.html"},{"key":"e_1_3_2_71_1","doi-asserted-by":"crossref","unstructured":"World Health Organization . Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. March 2020 (2020). www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected","DOI":"10.15557\/PiMR.2020.0003"},{"key":"e_1_3_2_72_1","unstructured":"Nicholas J BeechingTEF FowlerRobert. BMJ Best Practice: coronavirus disease 2019 (COVID-19) (2020). https:\/\/bestpractice.bmj.com\/topics\/en-gb\/3000168"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102523"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001191"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"e_1_3_2_79_1","unstructured":"Bergin C PhilbinM GilvarryP O'connorM KingF. Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARS-CoV-2 (COVID-19). ww.hse.ie\/eng\/about\/who\/acute-hospitals-division\/drugs-management-programme\/guidelines\/specific-antiviral-therapy-in-the-clinical-management-of-acute-respiratory-infection-with-sars-cov-2-covid-19.pdf"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2020.01012"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202002.0242.v1"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.90.2.223"},{"issue":"8","key":"e_1_3_2_84_1","first-page":"420","article-title":"Drug interaction monitoring of lopinavir \/ ritonavir in COVID-19 patients with cancer","volume":"59","author":"Zheng XW","year":"2020","unstructured":"Zheng XW , TaoG , ZhangYW , YangGN , HuangP. Drug interaction monitoring of lopinavir \/ ritonavir in COVID-19 patients with cancer. Zhonghua Nei Ke Za Zhi59(8(4)), 420\u2013422 (2020).","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_3_2_85_1","unstructured":"Clinicaltrials.Gov . Clinical trials on Favipiravir role in SARS-COV-2 infection. (2020). https:\/\/clinicaltrials.gov\/ct2\/results?cond=covid+19&term=Favipiravir+&cntry=&state=&city=&dist="},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"e_1_3_2_87_1","unstructured":"Clinicaltrials.Gov . Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734\u2122) in Participants With Severe Coronavirus Disease (COVID-19). (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292899"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2398"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2403"},{"key":"e_1_3_2_90_1","unstructured":"Health NIO . NIH clinical trial of remdesivir to treat COVID-19 begins. (2020). www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-remdesivir-treat-covid-19-begins"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117477"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25707"},{"key":"e_1_3_2_93_1","unstructured":"Clinicaltrials.Gov . An Open-label Randomized Controlled Trial on Lopinavir\/ Ritonavir Ribavirin and Interferon Beta 1b Combination Versus Lopinavir\/ Ritonavir Alone as Treatment for 2019 Novel Coronavirus Infection. (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688"},{"issue":"1","key":"e_1_3_2_94_1","first-page":"0","article-title":"Management of corona virus disease-19 (COVID-19): the Zhejiang experience","volume":"49","author":"Xu K","year":"2020","unstructured":"Xu K , CaiH , ShenYet al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue xue bao. Yi xue ban=Journal of Zhejiang University. Med. Sci.49(1), 0\u20130 (2020).","journal-title":"Zhejiang da xue xue bao. Yi xue ban=Journal of Zhejiang University. Med. Sci."},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.002"},{"key":"e_1_3_2_96_1","unstructured":"Clinicaltrials.Gov . Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus. (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04260594"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12084690.v2"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0275.v1"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105945"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-019-0132-8"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237"},{"key":"e_1_3_2_104_1","unstructured":"Srivatsan Padmanabhan M . Potential dual therapeutic approach against SARS-CoV-2\/COVID-19 with nitazoxanide and hydroxychloroquine."},{"key":"e_1_3_2_105_1","unstructured":"Chctr.Org . Clinical Trials on Chloroquine for SARS-COV-2 infection. (2020). http:\/\/www.chictr.org.cn\/searchprojen.aspx"},{"key":"e_1_3_2_106_1","unstructured":"Clinicaltrials.Gov . Clinical trials on chloroquine (2020). https:\/\/clinicaltrials.gov\/ct2\/results?cond=Covid+19&term=chloroquine&cntry=&state=&city=&dist="},{"key":"e_1_3_2_107_1","unstructured":"Clinicaltrials.Gov . Various Combination of Protease Inhibitors Oseltamivir Favipiravir and Chloroquin for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19). (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04303299"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.22.002386"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/xcdary"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.23812\/CONTI-E"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"e_1_3_2_113_1","volume-title":"Pharmacotherapy Principles and Practice.","author":"Chisholm-Burns MA","year":"2016","unstructured":"Chisholm-Burns MA , WellsBG , SchwinghammerTL. Pharmacotherapy Principles and Practice.McGraw-Hill,NY, USA (2016)."},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60454-7"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117"},{"key":"e_1_3_2_117_1","unstructured":"Clinicaltrials.Gov . Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) (TOCIVID-19). (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04317092?term=tocilizumab&cond=Covid+19&draw=2&rank=1"},{"key":"e_1_3_2_118_1","unstructured":"Clinicaltrials.Gov . Tocilizumab for SARS-CoV2 Severe Pneumonitis (NCT04315480). (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315480"},{"key":"e_1_3_2_119_1","unstructured":"Chctr.Org . Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter Randomized Controlled Trial (2020). www.chictr.org.cn\/showprojen.aspx?proj=51126"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047"},{"key":"e_1_3_2_121_1","unstructured":"Clinicaltrials.Gov . Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315298"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0302"},{"key":"e_1_3_2_123_1","unstructured":"Clinicaltrials.Gov . The efficacy and safety of bevacizumab in severe or critical patients with COVID-19 pneumonia \u2013 a multi-centered randomized controlledclinical trial. (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04305106?term=Bevacizumab&cond=covid+19&draw=2&rank=1"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.06.20032342"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000000791"},{"key":"e_1_3_2_126_1","unstructured":"Clinicaltrials.Gov . Glucocorticoid therapy for novel coronavirus. (2020). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04244591?term=Glucocorticoid&cond=COVID+19&draw=2&rank=1"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202003.0319.v1"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104787"},{"key":"e_1_3_2_129_1","doi-asserted-by":"crossref","unstructured":"Patel A DesaiS. Ivermectin in COVID-19 related critical illness. Available at SSRN 3570270 (2020). https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3570270","DOI":"10.2139\/ssrn.3570270"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.017"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41587-020-00003-1"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23208"},{"key":"e_1_3_2_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0153-3"},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30304-4"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12186"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12186"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01248-09"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22211.2"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C300520200"},{"key":"e_1_3_2_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.5631"},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2020.02.005"},{"issue":"2","key":"e_1_3_2_142_1","first-page":"119","article-title":"Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"Liu X","year":"2020","unstructured":"Liu X , WangX-J. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv47(2), 119\u2013121 (2020).","journal-title":"bioRxiv"},{"key":"e_1_3_2_143_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1085658"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502577200"},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.45538"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-020-3192-6"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104743"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.03.036"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-0233-6"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c00272"}],"container-title":["Therapeutic Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/tde-2020-0035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:04:33Z","timestamp":1715947473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/tde-2020-0035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.4155\/tde-2020-0035"],"URL":"https:\/\/doi.org\/10.4155\/tde-2020-0035","relation":{},"ISSN":["2041-5990","2041-6008"],"issn-type":[{"value":"2041-5990","type":"print"},{"value":"2041-6008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=itde20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}